// App-Quantinova.ai

MA03.01 : EPICAL Trial. A Phase Ib StudyCombining Anti-Epidermal Growth Factor (EGF) Vaccination With Afatinib in EGFR-Mutant Non-Small Cell Lung Cancer

Researchers

Presenter

  • D. Rodriguez Abreu

Principal Investigators

  • M. Cobo

  • S. Viteri

  • M. Gonzalez-Cao

  • S. Garcia-Roman

  • B. Garc�a Pel�ez

  • R. Rosell

Medical Centers

  • Medical Oncology, Dr Rosell Oncology Institut, General de Cataluña University Hospitalcataluña , Quironsalud Group, Barcelona, Spain, Sant Cugat Del Valles/ES

  • In3Bio, Sheffield/GB

  • Oncology Institute Dr. Rosell, Ior, Quirón-Dexeus University Institute, Barcelona/ES

  • Instituto Oncológico Dr. Rosell (Ior), Quirón-Dexeus University Hospital, Barcelona/ES

  • Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria/ES

  • Laboratory of Oncology / Panagaea Oncology, Barcelona, Spain

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Oncology Institut Dr Rosell, Dexeus University Hospital-Quironsalud Group, Barcelona, Spain

  • Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional Y Virgen de La Victoria, Ibima, Málaga/ES

  • Molecular Laboratory, Pangaea Oncology, Spain/ES

Locations

  • Spain

  • United Kingdom

  • Venezuela

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

  • Coronavirus disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Afatinib

Outcome

  • N/A

Study Design

  • Single Arm

Phase

  • I

Study Id's

  • NCT03623750

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved